|
顯示項目 707791-707800 / 2348487 (共234849頁)
<< < 70775 70776 70777 70778 70779 70780 70781 70782 70783 70784 > >>
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2022-04-14T23:27:36Z |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer
|
YI-HSIN LIANG; JIN-TUNG LIANG; Lin, Ben Ren; TAI-CHUNG HUANG; JI-SHIANG HUNG; Lai, Shuo Lun; Chen, Tzu Chun; JIA-HUEI TSAI; Cheng, Yung Ming; Tsao, Ting Han; Hsu, Wen Ling; Chen, Kuo Hsing; KUN-HUEI YEH |
| 臺大學術典藏 |
2022-04-20T03:25:50Z |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer
|
Liang, Yi-Hsin; JIN-TUNG LIANG; Lin, Ben-Ren; TAI-CHUNG HUANG; Hung, Ji-Shiang; Lai, Shuo-Lun; Chen, Tzu-Chun; Tsai, Jia-Huei; Cheng, Yung-Ming; Tsao, Ting-Han; Hsu, Wen-Ling; Chen, Kuo-Hsing; Yeh, Kun-Huei |
| 臺大學術典藏 |
2022-04-20T05:36:35Z |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer
|
Liang, Yi-Hsin; Liang, Jin-Tung; BEEN-REN LIN; TAI-CHUNG HUANG; Hung, Ji-Shiang; Lai, Shuo-Lun; Chen, Tzu-Chun; Tsai, Jia-Huei; Cheng, Yung-Ming; Tsao, Ting-Han; Hsu, Wen-Ling; Chen, Kuo-Hsing; Yeh, Kun-Huei |
| 臺大學術典藏 |
2022-07-26T08:38:07Z |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer
|
Liang, Yi-Hsin; Liang, Jin-Tung; Lin, Ben-Ren; TAI-CHUNG HUANG; Hung, Ji-Shiang; Lai, Shuo-Lun; Chen, Tzu-Chun; JIA-HUEI TSAI; Cheng, Yung-Ming; Tsao, Ting-Han; Hsu, Wen-Ling; Chen, Kuo-Hsing; Yeh, Kun-Huei |
| 臺大學術典藏 |
2022-08-12T02:50:36Z |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer
|
Liang Y.-H.; Liang J.-T.; Lin B.-R.; Huang J.; Hung J.-S.; Lai S.-L.; Chen T.-C.; Tsai J.-H.; Cheng Y.-M.; Tsao T.-H.; Hsu W.-L.; Chen K.-H.; KUN-HUEI YEH |
| 臺大學術典藏 |
2019-03-04T08:08:05Z |
Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials
|
Cheng, Rebecca;Chung, Hyun Cheol;Orlando, Mauro;Mi, Gu;Binder, Polina;Zhang, Yawei;Sohn, JooHyuk;Yamazaki, Kentaro;Kim, Sang-We;Chao, Yee;Lee, Keun-Wook;Kudo, Masatoshi;Kim, Tae-Won;Muro, Kei;Yen, Chia-Jui;JIN-YUAN SHIH; Yen, Chia-Jui; Muro, Kei; Kim, Tae-Won; Kudo, Masatoshi; JIN-YUAN SHIH; Lee, Keun-Wook; Chao, Yee; Kim, Sang-We; Yamazaki, Kentaro; Sohn, JooHyuk; Cheng, Rebecca; Zhang, Yawei; Binder, Polina; Mi, Gu; Orlando, Mauro; Chung, Hyun Cheol |
| 臺大學術典藏 |
2020-08-13T06:33:32Z |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Zhang Y.; Sohn J.; Cheng R.; Yamazaki K.; Kim S.-W.; Chao Y.; Lee K.-W.; JIN-YUAN SHIH; Kudo M.; Kim T.-W.; Muro K.; Yen C.-J.; Yen C.-J.;Muro K.;Kim T.-W.;Kudo M.;Jin-Yuan Shih;Lee K.-W.;Chao Y.;Kim S.-W.;Yamazaki K.;Sohn J.;Cheng R.;Zhang Y.;Binder P.;Mi G.;Orlando M.;Chung H.C.; Binder P.; Mi G.; Orlando M.; Chung H.C. |
| 國立成功大學 |
2018 |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Yen, C.-J.;Muro, K.;Kim, T.-W.;Kudo, M.;Shih, J.-Y.;Lee, K.-W.;Chao, Y.;Kim, S.-W.;Yamazaki, K.;Sohn, J.;Cheng, R.;Zhang, Y.;Binder, P.;Mi, G.;Orlando, M.;Chung, H.C. |
| 國家衛生研究院 |
2013-11-06 |
Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma
|
Chang, KC;Chang, WC;Chang, Y;Hung, LY;Lai, CH;Yeh, YM;Chou, YW;Chen, CH |
| 國立成功大學 |
2013-11-06 |
Ran GTPase-Activating Protein 1 Is a Therapeutic Target in Diffuse Large B-Cell Lymphoma
|
Chang, Kung-Chao; Chang, Wei-Chao; Chang, Yao; Hung, Liang-Yi; Lai, Chien-Hsien; Yeh, Yu-Min; Chou, Yu-Wei; Chen, Chung-Hsuan |
顯示項目 707791-707800 / 2348487 (共234849頁)
<< < 70775 70776 70777 70778 70779 70780 70781 70782 70783 70784 > >>
每頁顯示[10|25|50]項目
|
